Benzinga | Jun 28, 2021 05:40AM EDT

JP Morgan Downgrades Global Blood Therapeutics to Neutral, Announces $36 Price Target

JP Morgan analyst Tessa Romero downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and announces $36 price target.